Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended

Fulcrum Therapeutics, Inc.

REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.
All secondary endpoints (MFI, shoulder strength, PROs) did not reach statistical significance.
Fulcrum suspends losmapimod development; safety profile consistent with prior studies.
$273.8M cash as of June 30 used for pociredir (SCD), DBA programs, and early discovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.